RE:Genentech exploring mRNA vaccine for Pancreatic Cancer In 2016 Genentech agreed to pay BioNTech $310 million in upfront and “near-term” payments in a collaboration that was aimed at developing mRNA vaccines to treat multiple cancer types. The companies also agreed to share equally all development costs and any potential profits for certain programs.
In June 2016 , Merck & Co. and Moderna Therapeutics launched a $200 million partnership in a scramble to develop mRNA-based personalized cancer immunotherapies.
https://www.genengnews.com/topics/omics/genentech-biontech-to-partner-on-mrna-cancer-vaccines/
Since ONCY never entered into an upfront payment with any Big Pharma partner, ONCY's fair value is well in excess of UD$8 Billion on the strength of ONCY's shareholders having carryied all the costs associated with ONCY's clinical trial program in various cancers. Having ONCY shareholders carry the entire costs either happened by plan or happenstance but eitherway ONCY's value is not tied to any particular company's upfront payment, so the acquiition value of pelareorep and the company is now before any Big Pharma company who will make the highest acceptable offer - which now is estimated in excess of US$8 Billion - at a time when Big Pharma is faced with a looming patent cliff that can only be addressed through M&A and the 'bolt-on' acquistion of external assets that complement the acquirer's product pipeline, as ONCY's pelareorep is capable of accomplishing.